Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 6Brain Neoplasms 4Oligodendroglioma 3Lymphoma, Follicular 3Gliosarcoma 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Optic Nerve Glioma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Sezary Syndrome 1Renal Insufficiency 1Recurrence 1Primary Myelofibrosis 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × Cilengitide × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡